Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Hikma Pharmaceuticals Plc ADR (HKMPY)

Hikma Pharmaceuticals Plc ADR (HKMPY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals Newswire.ca - Fri Apr 29, 2022

/CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire...

HKMPY : 49.0150 (+6.19%)
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab) Business Wire - Fri Aug 27, 2021

Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal...

HIK.LN : 1,960.000 (+1.82%)
HKMPY : 49.0150 (+6.19%)
Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region Business Wire - Thu Apr 29, 2021

Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ®...

HIK.LN : 1,960.000 (+1.82%)
HKMPY : 49.0150 (+6.19%)
Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa Business Wire - Tue Dec 1, 2020

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical...

SESN : 12.5760 (+7.29%)
HIK.LN : 1,960.000 (+1.82%)
HKMPY : 49.0150 (+6.19%)
Hikma and Arecor Expand Collaboration Globe NewsWire - Tue Oct 20, 2020

LONDON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today's...

HIK.LN : 1,960.000 (+1.82%)
HKMPY : 49.0150 (+6.19%)

Barchart Exclusives

Tesla Stock Put Options Are Still Highly Priced - Ideal for Shareholders to Sell Short for Income Barchart - 30 minutes ago
Tesla Inc. put options in near-term expiry periods are still at high premium levels, even after TSLA stock has rebounded. This is ideal for existing shareholders to sell short to gain extra income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot